Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2009 Publisher: Sanofi-aventis, One Onslow Street, Guildford, Surrey, GU1 4YS, UK
Distigmine is an inhibitor of cholinesterase by the formation of complexes with the enzyme. This process is reversible. Specific cholinesterase or acetylcholinesterase is inhibited more strongly than pseudo or plasma cholinesterase.
Maximum inhibition of plasma cholinesterase occurs 9 hours after a single intramuscular dose and persists for about 24 hours.
Tritium labelled Ubretid was used to determine the urinary and biliary excretion of the drug in the rat. Activity in the urine was demonstrated quickly, amounting to 43% after 8 hours. Biliary excretion was shown to be insignificant. In man, results suggested that about 50% of a 0.5mg 1ml dose was excreted in 24 hours.
There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
